Once again, investors are asked to parse the difference between legal and ethical.
The Sacklers would be removed from ownership and would contribute $4.5 billion, but they would be shielded from any future lawsuits over opioids.
J&J said that trial participants who received a booster shot had a “nine-fold” increase of virus-fighting antibodies compared to what was observed four weeks after the initial dose.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.
| Website: | www.jnj.com |
| Email: | invest@surgeenergy.ca |
| Main Phone: | +1 732 524-0400 |
| Address: | One Johnson and Johnson Plaza |
| Address 2: | Suite 2100 |
| State: | NJ |
| City / Town: | New Brunswick |
| Country: | US |
| Postal Code: | 08933 |
| Exchange: | NYE |
| CEO: | Alex Gorsky |
| Employees: | 136400 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Once again, investors are asked to parse the difference between legal and ethical.
The Sacklers would be removed from ownership and would contribute $4.5 billion, but they would be shielded from any future lawsuits over opioids.
J&J said that trial participants who received a booster shot had a “nine-fold” increase of virus-fighting antibodies compared to what was observed four weeks after the initial dose.
The cities join New York in this measure designed to contain the fast-spreading Delta variant of the coronavirus.
Company leaders called it a matter of safety and cited “incredibly compelling” evidence of the effectiveness of the vaccines.
Sources say the FDA has set an unofficial deadline of Labor Day to render a decision.
India's drug regulator announced that J&J had pulled its application seeking an accelerated approval for local trials.
Hundreds of thousands of COVID-19 vaccine doses have been saved from the trash after U.S. regulators extended their expiration date for a second time.
The vaccines being produced won't be distributed until the FDA confirms the plant's conditions meet all standards for safety, effectiveness and manufacturing quality.
Attorneys general from 15 states need to convince thousands of local governments to accept the deal.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
